
Carbizol5 mg
Square Pharmaceuticals PLC.
Carbimazole is an antithyroid medicine used to reduce excessive thyroid hormone production.
Carbimazole is an antithyroid medicine used to reduce excessive thyroid hormone production. Its indications can be classified by strength of evidence as follows:
Carbimazole is not used to treat hypothyroidism, simple (non-toxic) goitre, or thyroid cancer.
The dose of Carbimazole and the length of treatment depend on the indication, the severity of thyrotoxicosis, and the individual's response, and must be guided by regular clinical assessment and monitoring of thyroid function tests.
| Indication / Population | Typical dosing |
|---|---|
| Adults - initial treatment of hyperthyroidism (Graves' disease, toxic nodular goitre) | Usually 20-40 mg once daily or in divided doses (up to 60 mg/day in severe thyrotoxicosis), continued until euthyroid, generally over 4-8 weeks |
| Adults - maintenance (titration regimen) | Gradually reduced to the lowest effective maintenance dose, typically 5-15 mg once daily, once thyroid function has normalised |
| Adults - "block-and-replace" regimen | A fixed higher dose (e.g. around 40 mg/day) is continued together with added levothyroxine to keep the patient euthyroid |
| Pre-operative preparation for thyroidectomy | Dosed as above until euthyroid; iodine is often added shortly before surgery per specialist protocol |
| Pre-treatment before radioactive iodine therapy | Dosed as above to achieve a euthyroid state; typically stopped for a short period before radioactive iodine administration on specialist advice, as it may reduce treatment efficacy |
| Children and adolescents | Individualised, weight-based dosing under specialist (paediatric endocrinology) supervision; treatment is initiated at a lower dose and carefully titrated |
| Elderly | Usual adult doses are generally used, with close monitoring given a higher likelihood of comorbidities |
Carbimazole tablets are taken by mouth, with or without food, and should be swallowed whole with water. Doses are best taken at the same time(s) each day. Patients should not stop, increase, or reduce the dose of Carbimazole without medical advice, and must attend all scheduled blood tests (thyroid function tests and complete blood counts) throughout treatment. The total duration of a course of Carbimazole for Graves' disease is typically 12-18 months, after which a trial withdrawal may be considered under specialist supervision (see Duration of Treatment).
Most patients tolerate Carbimazole well, but side effects can occur.
Carbimazole is contraindicated in the following situations:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.